Compare Cheniere Energy (LNG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cheniere Energy vs Natera Inc. Common Stock — how do they compare? Cheniere Energy trades at $280.95 (market cap $59.26B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Cheniere Energy and Natera Inc. Common Stock are close in size by market cap, and Cheniere Energy pays a 0.77% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and Natera Inc. Common Stock for 0 Days on average.
| LNG | NTRA | |
|---|---|---|
Market Cap | $59.26B | $57.03B |
Volume | 1,056,751 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $296.91 | $425.64 |
52-Week Low | $188.83 | $179.42 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $84.72B | $56.18B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cheniere Energy
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
